期刊文献+

螺内酯对严重心力衰竭患者神经体液和左心室功能的影响──附70例报告 被引量:6

The effects of spironolactone on neurohumour and left ventricular function in patients with severe heart failure.
下载PDF
导出
摘要 目的 :探讨螺内酯对严重心力衰竭 (心衰 )患者血浆脑钠素、心钠素、血管紧张素Ⅱ(angiotensinⅡ ,AngⅡ )、醛固酮水平及左心室功能的影响。方法 :137例严重心衰患者随机分为螺内酯组(70例 ,螺内酯 2 0~ 4 0mg/d)和常规治疗组 (6 7例 )。治疗前和治疗 3、 6个月时分别检测血浆脑钠素、心钠素、AngⅡ、醛固酮水平 ,心脏超声测量左心室功能参数的变化。结果 :①螺内酯组和常规治疗组在治疗 3、 6个月时血浆脑钠素水平 [(5 4 9± 170 )ng/L ,(4 98± 16 5 )ng/L对 (6 11± 174 )ng/L ,(5 79± 16 8)ng/L ;P <0 0 5、P <0 0 1]、心钠素水平 [(190± 2 8)ng/L ,(16 9± 2 6 )ng/L对 (2 0 9± 30 )ng/L ,(184± 2 7)ng/L ,P <0 0 1,P <0 0 1]均较治疗前脑钠素水平 [(6 6 1± 189)ng/L ,(6 75± 183)ng/L]及心钠素水平[(2 2 1± 31)ng/L ,(2 2 0± 30 )ng/L]明显下降 ,前者 2项指标在治疗 3、 6个月时较后者下降更明显 (均为P <0 0 5 ) ;螺内酯组治疗 3、 6个月时血浆AngⅡ [(2 74± 86 )ng/L ,(2 80± 92 )ng/L]、醛固酮水平 [(347± 71)pmol/L ,(345± 71)pmol/L]较治疗前 [(2 6 6± 10 4 )ng/L ,(339± 6 7)pmol/L]无明显下降 ,而常规治疗组治疗 3个月时均明显下降 [(2 36± 80 )ng/L ,(2 93± 5 4 ) Objective: To evaluate the effects of spironolactone on the plasma levels of brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), angiotensin Ⅱ (AngⅡ), aldosterone (ALD) and left ventricular function in patients with severe heart failure. Methods: One hundred and thirty seven patients with severe heart failure were randomly divided into spironolactone group (spironolactone 20~40 mg/d,n=70) and the routine treatment group(n=67). Plasma concentrations of BNP, ANP, AngⅡ, and ALD were measured, and left ventricular function was assessed with echocardiography at study entry, after 3 and 6 months of treatment. Results: ① In spironolactone group and in the routine treatment group after 3 and 6 months of treatment, the plasma levels of BNP [(549±170)ng/L, (498±165)ng/L and(611±174)ng/L,(579±168)ng/L, respectively; P<0.05, P<0.01] and ANP[(190±28)ng/L,(169±26)ng/L and (209±30)ng/L, (184±27)ng/L, respectively;P<0.01, P<0.01] were significantly decreased in comparison with the plasma levels of BNP [(661±189)ng/L, (675±183)ng/L] and ANP [(221±31)ng/L, (220±30)ng/L] before treatment. The reduction of plasma levels of BNP and ANP after 3 and 6 months of treatment were more remarkable in spironolactone group than that in the routine treatment group (P<0.05, P<0.05). After 3 and 6 months of treatment, the plasma levels of AngⅡ[(274±86)ng/L, (280±92)ng/L] and ALD [(347±71)pmol/L,(345±71)pmol/L] were not significantly decreased in comparison with the plasma levels of AngⅡ [(266±104)ng/L] and ALD [(339±67)pmol/L] before treatment in spironolactone group;while in the routine treatment group, AngⅡ and ALD were markedly decreased after 3 months of treatment [(236±80)ng/L, (293±54)pmol/L,P<0.05, P<0.01], and increased after 6 months of treatment [(262±88)ng/L, (337±51)pmol/L] near the levels before treatment[(271±97)ng/L, (326±55)pmol/L]. ②Before treatment, there were no significant difference between two groups in left ventricular diastole internal diameter (LVDd), left ventricular ejective fraction (LVEF), and heart rate (HR) (P>0.05,P>0.05,P>0.05).However, there were significant improvement of LVDd, LVEF, and HR in two groups(P<0.05,P<0.05,P<0.05)after 3 and 6 months of treatment, and the improvement of LVEF and cardia function in spironolactone group was more remarkable than in control group (P<0.05,P<0.05). Conclusion: Spironolactone administration in patients with severe heart failure can decrease the plasma level of BNP and ANP, improve cardiac function effectively.
出处 《新医学》 北大核心 2004年第6期332-334,共3页 Journal of New Medicine
关键词 螺内酯 心力衰竭 神经体液 左心室功能 脑钠素 心钠素 血管紧张素 醛固酮 Spironolactone Heart failure Brain natriuretic peptide Atrial natriuretic peptide Angiotensin Aldosterone
  • 引文网络
  • 相关文献

参考文献7

  • 1Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med,1999, 341 (10): 709-717.
  • 2Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation, 1990, 82 (5): 1724-1729.
  • 3Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med,1998, 339 (5): 321-328.
  • 4Selvais PL, Robert A, Ahn S, et al. Direct comparison between endothelin1 N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J Card Fail,2000, 6 (3): 201-207.
  • 5Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail, 1996, 2 (1): 47-54.
  • 6Tsutamoto T, Wada A, Zaeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol, 2001, 37 (5): 1228-1233.
  • 7Beggah AT, Escoubet B, Puttini S, et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci USA,2002, 99 (10): 7160-7165.

同被引文献28

  • 1彭穗玮,黄守坚.治疗慢性充血性心力衰竭药物简介[J].新医学,2004,35(9):570-572. 被引量:12
  • 2陈德明,郭文涛,李云富,党彦平,丁学智,耿壮丽.通心络对冠心病患者血管内皮依赖性舒张功能的影响[J].实用全科医学,2005,3(1):20-21. 被引量:13
  • 3许慧,杜争鸣,刘树英,刘培菊,刁克,刁平然.充血性心力衰竭患者血浆内皮素改变及卡托普利疗效分析[J].医学理论与实践,2005,18(1):6-8. 被引量:5
  • 4KRUM H. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure [ J ]. Eur Heart J, 2005, 26 (22) : 2473- 2474.
  • 5CLELAND J G, TENDERA M, ADAMUS J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study[J]. Eur Heart J, 2006, 27 (19) : 2338-2345.
  • 6YOSHIYAMA M, OMURA T, YOSHIKAWA J. Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin Ⅱ type I receptor antagonist in rats with myocardial infarction [J]. Nippon Yakurigaku Zasshi, 2004, 124(2) : 83-89.
  • 7LACOLLEY P, SAFAR M E, LUCET B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats [ J]. J Am Coll Cardiol, 2001, 37 (2) : 662-667.
  • 8TSUTAMOTO T, WADA A. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure [ J ]. J Am Coll Cardiol, 2001, 37 (5) : 1228-1233.
  • 9张素华,张利宣,赵维江,曹治宸,黄建敏,潘丽萍.螺内酯对老年舒张性心力衰竭患者血清Ⅰ型前胶原羧基端肽水平的影响[J].中国心血管杂志,2007,12(4):281-283. 被引量:3
  • 10中华人良共和国卫生部.中药新药研究指导原则[S](第2辑).1995:57-63

引证文献6

二级引证文献5

;
使用帮助 返回顶部